MAINTAINED REDUCTION OF UTERINE LEIOMYOMA FOLLOWING ADDITION OF HORMONAL REPLACEMENT THERAPY TO A MONTHLY LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST IMPLANT - A PILOT-STUDY

被引：38

作者：

MAHEUX, R

LEMAY, A

BLANCHET, P

FRIEDE, J

PRATT, X

机构：

[1] Research Centre, Hôpital St-François d'Assise, Quebec G1L 3L5, 10, de l'Espinay

[2] Department of Obstetrics and Gynaecology, Hôpital du Saint-Sacrement, Quebec G1L 3L5, 10, de l'Espinay

[3] Department of Obstetrics and Gynaecology, Hôtel-Dieu de Québec, Quebec G1L 3L5, 10, de l'Espinay

[4] Department of Nuclear Medicine, Hôpital St-François d'Assise, Quebec G1L 3L5, 10, de l'Espinay

来源：

HUMAN REPRODUCTION | 1991年 / 6卷 / 04期

基金：

英国医学研究理事会;

关键词：

CONJUGATED ESTROGENS; LEIOMYOMA; LHRH AGONIST;

D O I：

10.1093/oxfordjournals.humrep.a137367

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Ten pre-menopausal women with uterine leiomyoma were treated for 1 year with a monthly depot of luteinizing hormone-releasing hormone agonist (LHRA-a), goserelin, combined after the initial 3 months of treatment with conjugated oestrogens 0.3 mg (days 1-25) and medroxyprogesterone acetate 5 mg (days 16-25). Mean leiomyoma volume decreased by 49.3% during the first 3 months when goserelin alone was administered but did not change significantly during the 9 months of combination therapy. There were no significant changes in bone mass or high-density lipoprotein cholesterol during the study whereas hot flushes and menstrual blood loss were well controlled. These results indicate that ovarian suppression with a monthly depot of the LHRH-a, goserelin, combined after 3 months with low-dose hormonal replacement therapy reduced the size and the symptomatology of leiomyoma while preserving the bone mass.

引用

页码：500 / 505

页数：6

共 18 条

[1]

Coddington C.C., Collins R.L., Shawker T.H., Erson R., Loriaux D.L., Winkel C.A., Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri. Fenil, Steril, 45, pp. 624-629, (1986)

[2]

Ettinger B., Genant H.K., Cann C.E., Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium, Ann. Intern. Med, 10, (1987)

[3]

Friedewald W.T., Levy R.I., Fredrickson D.S., Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge, Clin. Chem, 18, (1972)

[4]

Friedman A.J., Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: A pilot study. Fenil, Steril, 51, pp. 526-528, (1989)

[5]

Friedman A.J., Barbieri R.L., Benacerraf B.R., Schiff I., Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist, Fertil. Steril, 48, (1987)

[6]

Friedman A.J., Harrison-Atlas D., Barbieri R.L., Benacerraf B., Gleason R., Schiff I., A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil, Steril, 51, pp. 251-256, (1989)

[7]

Golan A., Bukovsky I., Schneider D., Ron R., Herman A., Caspi E., D-Trp-6-luteinizing hormone-releasing hormone microcapsules in the treatment of uterine leiomyomas, Fertil. Steril, 52, (1989)

[8]

Healy D.L., Lawson S.R., Abbott M., Baird D.T., Fraser H.M., Toward removing uterine fibroids without surgery: Subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase, J. Clin. Endocrinol. Metab, 63, (1986)

[9]

Hricak H., Tscholakoff D., Heinrichs L.R., Fisher M.R., Dooms G.C., Reinhold C., Jaffe R.B., Uterine leiomyomas: Correlation of MR, histopathologic findings, and symptoms, Radiology, 15, pp. 385-391, (1986)

[10]

Johansen J.S., Riis B.J., Hassager C., Moen M., Jacobson J., Christiansen C., The effect of a gonadotropin-releasing hormone agonist analog (Nafarelin) on bone metabolism, J. Clin. Endocrinol. Metab, 67, pp. 701-706, (1988)

← 1 2 →